ABSTRACT Introduction: The prevalence of Alzheimer's disease (AD) continues to rise,
while treatment options for cognitive impairment are limited. Acetylcholinesterase inhibitors …

Acetylcholinesterase inhibitors have been extensively tested in placebo-controlled studies
for use as symptomatic drugs in mild-to-moderate stages of Alzheimer's disease. Published …

Introduction: Alzheimer's disease (AD) is the most common cause of major neurocognitive
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …

The real efficacy of Acetyl-cholinesterase-inhibitors (AChEI) has been questioned. In this
narrative review we evaluated their effect on cognitive decline, measured by Mini Mental …

The 'second-generation'cholinesterase inhibitors (ChEIs), donepezil, galantamine and
rivastigmine, are a class of medications that are currently approved for the treatment of mild …

Introduction: To date, pharmacological treatment of Alzheimer's disease (AD) includes
Acetylcholinesterase Inhibitors (AChEIs) for mild-to-moderate AD, and memantine for …

Alzheimer's disease is a growing problem in an aging Western world, estimated to have cost
the US economy $1.75 trillion. Until recently, the management of Alzheimer's disease largely …

Alzheimer's disease (AD) is a chronic disabling disease that affects the central nervous
system. The main consequences of AD include the decline of cognitive functions and …

Alzheimer's disease (AD) is the most common form of dementia over the age of 65. It is
estimated that 115.4 million people will be affected by AD by 2050. Acetylcholinesterase …

Objectives To characterise the population of Alzheimer's disease patients treated with
acetylcholinesterase inhibitors, to analyse effectiveness and drug safety in the clinical …